Last reviewed · How we verify
NCT04443842
Behavioural Economics-based Incentives in Adults With Type 2 Diabetes Pilot Study
NA trial testing Financial and social incentives in Diabetes Mellitus, Type 2 in 11 participants. Completed in 7 December 2021.
6 September 2021
Quick facts
| Lead sponsor | The University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 1 November 2020 |
| Primary completion | 6 September 2021 |
| Estimated completion | 7 December 2021 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Financial and social incentives
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
The University of Hong Kong
Who can join
Adults 30 to 70, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A feasibility pilot study of a randomised control trial of adults newly diagnosed with type 2 diabetes to compare the effectiveness of financial and social incentives on healthy lifestyle behaviour.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04443842
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Financial and social incentives
Trials testing the same drug.
- NCT04917926 — Behavioural Economics-based Incentives in Adults With Type 2 Diabetes (BET2) · NA · completed
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other The University of Hong Kong trials
Trials by the same sponsor.
- NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
- NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
- NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
- NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
- NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04443842 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
- Last refreshed: 18 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04443842.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing